Cargando…

A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: case report

BACKGROUND: In recent years, the application of immunotherapy combined with chemotherapy in the first-line lung cancer has showed significant benefit in improving long-term survival. Immunotherapy also has risks of immune-related pneumonitis (IRP) after long-term treatment. Despite the treatment str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Yu, Chen, Cuncun, Zhao, Liming, Zhu, Xuyou, Zhu, Xiaoping, Li, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438889/ https://www.ncbi.nlm.nih.gov/pubmed/34521373 http://dx.doi.org/10.1186/s12890-021-01649-6

Ejemplares similares

Case Report: Nintedanib for immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with SMARCA4-mutant NSCLC: a case report
por: Deng, Changwen, et al.
Publicado: (2023)

A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti‐PD‐1 immune checkpoint antibody in a lung cancer patient
por: Jodai, Takayuki, et al.
Publicado: (2018)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
por: Yin, Jianqiong, et al.
Publicado: (2022)

Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
por: Ahn, June Hong
Publicado: (2020)

Clinical Management of Pneumonitis in Patients Receiving Anti–PD-1/PD-L1 Therapy
por: Bala-Hampton, Justin E., et al.
Publicado: (2018)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Gastrointestinal hemorrhage caused by duodenal metastasis from a primary lung adenocarcinoma: A case report
por: Zhu, Minjie, et al.
Publicado: (2021)

Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma
por: Yoo, Sang Hoon, et al.
Publicado: (2016)

Pneumonic‐type mucinous lung adenocarcinoma diagnosed by transbronchial cryobiopsy
por: Balestra, Rick, et al.
Publicado: (2017)

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy
por: Watanabe, Satoshi, et al.
Publicado: (2020)

Pneumonic-type lung adenocarcinoma presenting as non-obstructive lobar pneumonia
por: Papavasileiou, Vasileios, et al.
Publicado: (2023)

SAA suppresses α-PD-1 induced anti-tumor immunity by driving T(H)2 polarization in lung adenocarcinoma
por: Wang, Xin, et al.
Publicado: (2023)

Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
por: Zhang, Xuexia, et al.
Publicado: (2022)

Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports
por: Lu, Chieh-Sheng, et al.
Publicado: (2017)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed
por: Zhang, Pei, et al.
Publicado: (2017)

Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
por: Cheng, Yuan, et al.
Publicado: (2021)

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Anti-PD-1/PD-L1 and anti-CTLA-4 associated checkpoint inhibitor pneumonitis in non-small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
por: Hu, Xiao, et al.
Publicado: (2023)

Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer
por: Torresan, Sara, et al.
Publicado: (2023)

Differential diagnosis of localized pneumonic-type lung adenocarcinoma and pulmonary inflammatory lesion
por: Li, Qi, et al.
Publicado: (2022)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
por: Huang, Yafang, et al.
Publicado: (2019)

A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
por: Yakymenko, Dorthe, et al.
Publicado: (2023)

Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma
por: Wu, Fengying, et al.
Publicado: (2020)

The Pathology of the Pneumonic Lung
por: Sturges, Octavius
Publicado: (1873)

The Toxicity of Pneumonic Lungs
Publicado: (1918)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
por: Teng, Feifei, et al.
Publicado: (2020)

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
por: Ono, Kana, et al.
Publicado: (2021)

Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
por: Li, Yi‐hui, et al.
Publicado: (2021)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature
por: Bao, Zhiyao, et al.
Publicado: (2021)

Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature
por: Chen, Yu, et al.
Publicado: (2020)

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
por: Huang, Aiben, et al.
Publicado: (2021)

A false alarm of COVID-19 pneumonia in lung cancer with anti-PD-1 related pneumonitis: a case report and review of the literature
por: Dai, Ying, et al.
Publicado: (2021)

Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy
por: Neibart, Shane S., et al.
Publicado: (2023)

Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report
por: Ye, Xianghua, et al.
Publicado: (2022)

Pneumonic-type lung adenocarcinoma with different ranges exhibiting different clinical, imaging, and pathological characteristics
por: Huo, Ji-wen, et al.
Publicado: (2021)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s607g3u08b7sgma24b09d775c2